Treatment of SK-N-SH cells with morphine and interleukin-1beta (IL-1β) produced dual regulation of the mRNA for the human mu opioid receptor (MOR) protein. Morphine produced a decrease in the MOR mRNA while IL-1β increased it, as assessed by real-time quantitative PCR. These data were consistent with immunocytochemical studies of treated and untreated cells. Morphine-mediated down-regulation of MOR was blocked by naltrexone and IL-1β-induced up-regulation of MOR was blocked by interleukin-1 receptor type 1 antagonist. Immune-opioid crosstalk was examined by IL-1β and morphine co-treatment. These data are the first to show dual regulation of MOR in neuroblastoma cells.
Introduction
The pro-inflammatory cytokine, interleukin-1beta (IL-1β) plays a major role in host defense and inflammation and is increasingly associated with inflammatory pain and opioid analgesia. In rodent models, peripheral administration of IL-1β produced hyperalgesia (Ferreira et al., 1988; Oka et al., 1994; Watkins et al., 1994) and reduced morphine analgesia while contributing to morphine tolerance (Shavit et al., 2005) . At the molecular level, the interaction of IL-1β and the opioid system is shown by the finding that IL-1β increased the levels of mu opioid receptor (MOR) mRNA in primary astrocytes (Ruzicka et al., 1996; Ruzicka and Akil, 1997) and in neural microvascular endothelial cells (Vidal et al., 1998) . Other cytokines, including IFNα, TNFα, IL-4 and IL-6, also increase the expression of MOR in neuroblastoma (SH-SY-5Y) and peripheral immune cells (Börner et al., 2004 (Börner et al., , 2007 Kraus et al., 2001 Kraus et al., , 2006 . These results and others show that cytokines interact with endogenous opioid systems but explicit molecular mechanisms remain elusive.
IL-1β mediates its effects through the interleukin-1 receptor type 1 (IL1R1) protein, which is a member of the Toll-like/IL-1R1 (TIR) domain family of membrane receptors (O'Neill, 2002) . Like the Toll-like receptors, the IL1R1 receptor signals through a complex of accessory proteins and downstream signaling events including activation of the JAK-STAT, MAPK, and NF-κB pathways (Allan et al., 2005; Hibi and Hirano, 1998; Park et al., 2005; Wan et al., 2008) . The ultimate transcription factors from these pathways translocate to the nucleus and bind to regulatory regions on select genes to alter transcription. Genetic studies examining the structure of the human MOR gene regulatory regions found consensus sequences for cAMP response element (CRE, site of CREB regulation), activator-protein 1 (AP-1), and yin-yang-1 (YY-1) domains for transcriptional regulation (Wendel and Hoehe, 1998) . Functional studies in cell lines show that transcription factors from the JAK-STAT, MAPK and NF-κB signaling pathways alter mu opioid receptor gene transcription after cytokine stimulation (Kraus et al., 2001 (Kraus et al., , 2003 (Kraus et al., , 2006 .
Recent studies from our lab provided evidence of opioid and immune crosstalk in the regulation of NF-κB pathways using human astrocytes following treatment with opioid agonists and antagonists (Davis et al., 2007 (Davis et al., , 2008 . These opioid effects on cytokine-stimulated signaling pathways did not appear to be mediated by a classical opioid receptor in that these effects were not blocked by the general opioid antagonist, naltrexone, and were similar with opioid agonist and antagonist treatment. To examine opioid-immune crosstalk in a cell line with high levels of opioid receptors, the present study used SK-N-SH cells which express abundant and functional mu and delta opioid receptors (Baumhaker et al., 1993) . The SK-N-SH cells were immortalized from a neuroblastoma and are extensively used for studies of opioid receptor regulation and intracellular signaling (Baker et al., 2000; Bare et al., 1994; Baumhaker et al., 1993; Breivogel et al., 1997; Raut et al., 2007; Rubovitch et al., 2003; Sarne et al., 1998; Xu and Carr, 2001; Yu et al., 1986) .
We now report, for the first time in a neuroblastoma cell line, that treatment with IL-1β induces the increase of both MOR mRNA as assessed by real-time quantitative PCR and MOR protein levels as Journal of Neuroimmunology 227 (2010) 26-34 
